Launch One Acquisition Corp. Class A LPAA 深 沪
等待开盘 08-05 09:30:00 美东时间
10.43
0.000
0.00%
华盛通- 最 高10.4339
- 今 开10.42
- 成交量 4.61万股
- 最 低 10.42
- 昨 收 10.43
- 总市值 3.00亿
- 52周最高 10.70
- 市盈率 静 40.29
- 换手率 0.16%
- 52周最低 9.66
- 委 比 -61.64%
- 总股本 2875.00万
- 历史最高 10.70
- 量 比 0.37
- 振 幅 0.13%
- 历史最低 9.66
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth
Minovia Therapeutics reports positive interim results from its Phase 2 trial of MNV-201 for Pearson Syndrome, showing a favorable safety profile and early signs of efficacy in three patients. Two compassionate use patients with Kearns-Sayre syndrome also demonstrated improved quality of life. The FDA has granted Fast Track and Rare Pediatric Disease Designations to MNV-201. Minovia plans to finalize enrollment in the trial and advance toward pivo...
07-24 12:15
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: ATMCR, CRTAF, LPAA, and AFJKU
NEW YORK, July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
07-04 05:30
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
Minovia Therapeutics Ltd. announced that the U.S. FDA has granted Fast Track and Rare Pediatric Disease Designations to its lead compound MNV-201 for Pearson Syndrome, a life-threatening mitochondrial disorder. These designations aim to accelerate development and review, potentially reducing time to market and offering financial benefits via a pediatric priority review voucher. MNV-201 is a first-in-class mitochondrial cell therapy currently in P...
06-30 12:30
Launch One Announces Business Combination with Minovia
Launch One Acquisition Corp. Class A ( ($LPAA) ) has shared an update. On June ...
06-25 21:18
Minovia Therapeutics To Go Public Via Merger With Launch One Acquisition Corp., Forming Mito US One Ltd. To Advance Mitochondrial Therapies
Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing what it believes to be first-in-class therapies to treat mitochondrial diseases and combat age-related decline,
06-25 20:39
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. announce a definitive business combination agreement to create a publicly traded biotech company focused on mitochondrial augmentation technology (MAT). MAT addresses mitochondrial dysfunction across rare pediatric and common adult diseases. Minovia's lead product, MNV-201, has FDA Fast Track and Rare Pediatric Disease designations and is advancing towards pivotal trials. The transaction,...
06-25 12:30
南京市公安局江宁分局交警大队公告
转自：南京晨报 根据《中华人民共和国道路交通安全法》第112条和《中华人民共和国道路交通安全法实施条例》第107条规定，下列车辆因交通违法被依法扣留，经通知车...
2024-09-20 05:56
